MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)

Phase 1
Terminated
Conditions
Ovarian Neoplasms
Interventions
Drug: BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
Drug: BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
Drug: BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
First Posted Date
2011-04-06
Last Posted Date
2014-11-27
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
2
Registration Number
NCT01329549
Locations
🇯🇵

1199.117.003 Boehringer Ingelheim Investigational Site, Akashi, Hyogo, Japan

🇯🇵

1199.117.002 Boehringer Ingelheim Investigational Site, Chuo-ku,Tokyo, Japan

🇯🇵

1199.117.001 Boehringer Ingelheim Investigational Site, Hidaka, Saitama, Japan

A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients

Phase 3
Completed
Conditions
Hepatitis C
Interventions
Drug: PegIFN/RBV
First Posted Date
2011-04-06
Last Posted Date
2016-06-30
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
119
Registration Number
NCT01330316
Locations
🇨🇦

1220.48.1007 Boehringer Ingelheim Investigational Site, Victoria, British Columbia, Canada

🇺🇸

1220.48.0087 Boehringer Ingelheim Investigational Site, Baton Rouge, Louisiana, United States

🇺🇸

1220.48.0027 Boehringer Ingelheim Investigational Site, Framingham, Massachusetts, United States

and more 84 locations

Drug-drug Interaction of Empagliflozin (BI 10773) and Microgynon

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Microgynon + BI 10773
First Posted Date
2011-04-04
Last Posted Date
2014-06-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
18
Registration Number
NCT01328184
Locations
🇩🇪

1245.41.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer

Phase 2
Completed
Conditions
Breast Neoplasms
Interventions
First Posted Date
2011-03-29
Last Posted Date
2016-07-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
26
Registration Number
NCT01325428
Locations
🇹🇳

1200.89.21601 Boehringer Ingelheim Investigational Site, Ariana, Tunisia

🇺🇸

1200.89.10005 Boehringer Ingelheim Investigational Site, Durham, North Carolina, United States

🇦🇺

1200.89.61002 Boehringer Ingelheim Investigational Site, East Bentleigh, Victoria, Australia

and more 13 locations

Monotherapy Dose Finding With BI 847325 in Solid Tumours

Phase 1
Completed
Conditions
Neoplasms
Interventions
Drug: day 1 to day 14
Drug: day 1 to day 5
First Posted Date
2011-03-29
Last Posted Date
2018-12-21
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
69
Registration Number
NCT01324830
Locations
🇧🇪

1287.1.3201 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium

🇧🇪

1287.1.3202 Boehringer Ingelheim Investigational Site, Leuven, Belgium

Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types

Phase 1
Completed
Conditions
Neoplasms
Interventions
First Posted Date
2011-03-17
Last Posted Date
2016-05-30
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
64
Registration Number
NCT01317420
Locations
🇬🇧

1280.2.4401 Boehringer Ingelheim Investigational Site, Sutton, United Kingdom

🇬🇧

1280.2.4402 Boehringer Ingelheim Investigational Site, Leeds, United Kingdom

Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: placebo
First Posted Date
2011-03-16
Last Posted Date
2015-04-15
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
465
Registration Number
NCT01316380
Locations
🇦🇷

205.442.54003 Boehringer Ingelheim Investigational Site, Florencio Varela, Argentina

🇬🇹

205.442.50203 Boehringer Ingelheim Investigational Site, Guatemala, Guatemala

🇦🇷

205.442.54002 Boehringer Ingelheim Investigational Site, Capital Federal, Argentina

and more 59 locations

Twynsta Study With Lifestyle Modifications in Korean Patients With Hypertension

Completed
Conditions
Hypertension
Interventions
First Posted Date
2011-03-16
Last Posted Date
2015-09-21
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
2089
Registration Number
NCT01316419
Locations
🇰🇷

Boehringer Ingelheim Investigational Site 51, Jeju, Korea, Republic of

🇰🇷

Boehringer Ingelheim Investigational Site 54, Chonbuk, Korea, Republic of

🇰🇷

Boehringer Ingelheim Investigational Site 55, Busan, Korea, Republic of

and more 52 locations

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes Mellitus

Phase 1
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: Placebo
First Posted Date
2011-03-16
Last Posted Date
2014-06-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT01316341
Locations
🇨🇳

1245.44.86001 Boehringer Ingelheim Investigational Site, Beijing, China

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

Phase 1
Completed
Conditions
Ovarian Neoplasms
Peritoneal Neoplasms
Interventions
Drug: BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
Drug: BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
First Posted Date
2011-03-14
Last Posted Date
2025-02-13
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
19
Registration Number
NCT01314105
Locations
🇪🇸

Hospital Vall d'Hebron, Barcelona, Spain

🇪🇸

Hospital Clínic de Barcelona, Barcelona, Spain

🇪🇸

Hospital Duran i Reynals, L'Hospitalet de Llobregat, Spain

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy